KLF12 is a sequence-specific transcriptional repressor that binds DNA and regulates gene expression through RNA polymerase II-dependent mechanisms. It functions as a zinc-finger transcription factor with demonstrated repressive activity toward multiple target genes including AP-2-alpha, L1CAM, galectin-1, and genes involved in inflammatory pathways 123. Mechanistically, KLF12 exerts its effects through direct promoter binding and transcriptional suppression. Its activity is regulated post-translationally by the E3 ubiquitin ligase TRIM27, which ubiquitinates KLF12 at K326, modulating its transcriptional capacity 1. KLF12 also participates in regulatory loops involving long non-coding RNAs and microRNAs that control its stability and expression 45. Disease relevance spans multiple malignancies. KLF12 downregulation in esophageal squamous cell carcinoma promotes cisplatin resistance and metastasis through L1CAM upregulation 1. In immunotherapy contexts, KLF12 suppresses CD8+ T cell infiltration and function by repressing galectin-1, contributing to anti-PD-1 resistance 2. Conversely, in ovarian cancer, elevated KLF12 promotes cell proliferation and metastasis 5. KLF12 was identified as a frequent HPV integration site in cervical cancer 6. In airway inflammation, KLF12 suppresses lipopolysaccharide-induced inflammatory responses, oxidative stress, and pyroptosis via NF-κB pathway inhibition 3. Clinically, KLF12 represents a potential therapeutic target across multiple cancer types and inflammatory diseases.